Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Grows By 48.3%

Vivos Therapeutics, Inc. (NASDAQ:VVOSGet Free Report) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 305,500 shares, an increase of 48.3% from the May 15th total of 206,000 shares. Based on an average daily trading volume, of 96,800 shares, the short-interest ratio is presently 3.2 days. Approximately 6.7% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Ascendiant Capital Markets decreased their price target on Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating on the stock in a research note on Tuesday, April 15th. Alliance Global Partners downgraded shares of Vivos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 20th. Industrial Alliance Securities set a $2.25 target price on shares of Vivos Therapeutics in a report on Tuesday, May 20th. Finally, Wall Street Zen downgraded shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd.

View Our Latest Analysis on Vivos Therapeutics

Vivos Therapeutics Price Performance

NASDAQ VVOS opened at $2.16 on Wednesday. The stock’s 50 day simple moving average is $2.43 and its 200 day simple moving average is $3.43. Vivos Therapeutics has a one year low of $1.97 and a one year high of $6.28. The firm has a market cap of $12.72 million, a PE ratio of -1.25 and a beta of 7.02.

Vivos Therapeutics (NASDAQ:VVOSGet Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $3.63 million. Vivos Therapeutics had a negative return on equity of 170.43% and a negative net margin of 76.82%. During the same period in the prior year, the firm posted ($1.63) EPS. As a group, equities analysts expect that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cutter & CO Brokerage Inc. acquired a new stake in Vivos Therapeutics in the 4th quarter valued at about $163,000. Commonwealth Equity Services LLC grew its stake in shares of Vivos Therapeutics by 23.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Vivos Therapeutics by 55.6% in the fourth quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after purchasing an additional 16,025 shares in the last quarter. Anson Funds Management LP acquired a new stake in shares of Vivos Therapeutics in the fourth quarter valued at approximately $1,041,000. Finally, EWA LLC bought a new position in Vivos Therapeutics in the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

(Get Free Report)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Read More

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.